By 2030, orphan drugs will make up a fifth of the forecast $1.6 trillion in worldwide prescription drug sales – a share that has doubled over the last decade. While developers of niche drugs for rare diseases benefit from a range of regulatory and exclusivity advantages, the sales lifecycles of these therapies are beginning to look very similar to those of their mainstream counterparts.
In this report, we investigate the state of the orphan drug market out to 2030 and ask, are orphans really that different?
Access the report now to learn:
- What’s driving the slowdown in growth in the orphan drugs market
- Forecasts for the top-selling orphan drugs and companies in 2030
- The most promising therapies in the orphan drug pipeline.
